1 2 3 4

The Immune Regulation and Tolerance Research Group (IRT) meets three multidisciplinaryv laboratories working on Autoimmunity, Autoantigen discovery and Transplantation.

The different research lines are hosted by the Immunology Disciplinary Program of the Biomedical Sciences Institute (ICBM), located at the Faculty of Medicine, Universidad de Chile, Santiago, Chile. Our main goal is to understand the immunological basis responsible for the loss of tolerance in autoimmune diseases. We are intended to develop strategies for tolerance induction with therapeutic potential in autoimmunity and transplantation, emphasizing the study on tolerogenic dendritic cells, regulatory T and B cells, and cytokine-blocking antibodies. In addition, we have a commitment with the education, participating in the training of new scientific generations including undergraduate, graduate and postdoctoral fellows. Our main strength to transfer the achievements of our basic research into patients’ benefits is supported by a robust and productive interaction with several clinicians, including rheumatologists, hematologists, transplantologists and clinical immunologists.

publications

Take a glance at our latest publications

Corina Peña, David Gárate, Juan Contreras-Levicoy, Octavio Aravena, Diego Catalán, and Juan C. Aguillón. Dexamethasone Preconditioning Improves the Response of Collagen-Induced Arthritis to Treatment with Short-Term Lipopolysaccharide-Stimulated Collagen-Loaded Dendritic Cells.
Volume 2013 (2013), Article ID 296031. [+]

PROjECTS

Review our current and former grants

In the Immune Regulation and Tolerance Research Group we are developing the following projects, aimed to increase our knowledge in the mechanisms underlying the regulation of the immune system and to develop therapeutic strategies based in the induction in tolerance to treat autoimmune diseases and increase transplantation success. [+]

RESEARCH LINE

Use of tolerogenic dendritic cells (DCs) to restore tolerance in autoimmunity

It is now clear that DCs can be not only immunogenic but also tolerogenic. In particular, immature and semi-mature DCs have been found to have tolerogenic properties, and to induce regulatory CD4+ T cells (Treg and Tr1). In this context, we demonstrated the capacity of tolerogenic DCs to reduce the severity of autoimmunity in the collagen-induced arthritis (CIA) model for rheumatoid arthritis (RA). Briefly, we generated short-term lipopolysaccharide (LPS)-stimulated DCs pulsed with type II collagen (CII).[+]

Support and Links

Conicyt Fondef D09I1190 Fondecyt Instituto de Ciencias Biomedicas Millennium Institute on Immunology and ImmunotherapyPubMed
Sociedad Chilena de reumatología